Europium labeled lactosylated albumin as a model workflow for the development of biotherapeutics - Unité de Pharmacologie Chimique et Génétique
Article Dans Une Revue Nanomedicine: Nanotechnology, Biology and Medicine Année : 2019

Europium labeled lactosylated albumin as a model workflow for the development of biotherapeutics

Résumé

Lactosylated albumin is currently used as a radiopharmaceutical agent to image the liver asialoglycoprotein receptors and quantify hepatic liver function in various diseases. A lactosylated protein (LACTAL) conjugate showed excellent liver uptake compared to non-lactosylated protein and a high signal to noise ratio, based on the biodistribution in mice using 99mTc-scintigraphy. However, in the laboratory, it is useful to have a method that can be used in daily practice to quantify cellular targeting or biodistribution. We propose a methodology from synthesis validation to pre-clinical demonstration and introduce a new practical detector (LACTAL.Eu) of the LACTAL molecule in biological media. We confirmed the purity and colloidal stability of the sample through physical analytical techniques, then showed the absence of in vitro toxicity of the agent and demonstrated in vitro targeting. Taking advantage of the fluorescence decay of the lanthanide, we performed measurements directly on the cell media without any further treatment. Finally, biodistribution in mice was confirmed by ex vivo measurements.
Fichier principal
Vignette du fichier
S1549963419300425.pdf (1.05 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02123126 , version 1 (25-10-2021)

Licence

Identifiants

Citer

Hugo Salmon, Rabah Gahoual, Pascal Houzé, Tayssir Ibrahim, Michel Bessodes, et al.. Europium labeled lactosylated albumin as a model workflow for the development of biotherapeutics. Nanomedicine: Nanotechnology, Biology and Medicine, 2019, 18, pp.21-30. ⟨10.1016/j.nano.2019.02.011⟩. ⟨hal-02123126⟩
244 Consultations
72 Téléchargements

Altmetric

Partager

More